Submission of investor complaint for the quarter ended 30.06.2025 .
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) has filed its quarterly investor complaint report with BSE for the quarter ended 30 June 2025, as required under SEBI LODR Regulation 13(3). There were no pending investor complaints at the start of the quarter (1 April 2025). During the quarter, the company received just 1 investor complaint, which was fully resolved within the same period. As a result, zero complaints remained unresolved at the end of the quarter (30 June 2025). The filing was signed by Pooja Chuni, Company Secretary, and was also shared with the Ahmedabad Stock Exchange.
This is a routine regulatory filing showing very low investor grievance activity (1 complaint in 3 months), all of which were resolved. No meaningful impact on stock price or shareholder value; it simply confirms compliance with SEBI disclosure norms.